Hydrocodone/paracetamol controlled release

Drug Profile

Hydrocodone/paracetamol controlled release

Alternative Names: ABT-712; Acetaminophen/hydrocodone controlled release; Hydrocodone bitartrate/acetaminophen (HC/APAP) extended release - Abbott; Hydrocodone/acetaminophen controlled release; Paracetamol/hydrocodone controlled release; Vicodin CR

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Abbott Laboratories
  • Class Acetanilides; Morphine derivatives; Non-opioid analgesics; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid receptor agonists; Prostaglandin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Back pain; Osteoarthritis; Postoperative pain

Most Recent Events

  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 31 Oct 2011 Abbott completes a phase II trial in Chronic low back pain in USA (NCT01364922)
  • 26 Oct 2011 Abbott completes enrolment in its phase II trial for Chronic low back pain in USA (NCT01364922)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top